Summary
Boston Scientific Corporation (BSX) has announced the execution of a new $1.0 billion, 364-day credit agreement, dated February 27, 2020. This new facility, referred to as the '2020 Credit Agreement,' provides for a $1.0 billion Term Loan maturing on February 25, 2021. The primary purpose of this new loan is to refinance the outstanding balance of a previous term loan facility and cover related transaction costs. This move demonstrates proactive financial management by Boston Scientific, securing liquidity and optimizing its debt structure. The new credit agreement includes covenants related to a maximum leverage ratio, with provisions for a temporarily higher ratio following a 'Qualified Acquisition,' such as the previously completed BTG plc acquisition. This flexibility in covenants suggests the company may be anticipating further strategic acquisitions or growth initiatives.
Key Highlights
- 1Boston Scientific entered into a new $1.0 billion, 364-day credit agreement on February 27, 2020.
- 2The new agreement provides a $1.0 billion Term Loan maturing on February 25, 2021.
- 3The proceeds will be used to repay outstanding amounts under a previous $2.0 billion Term Loan Credit Agreement and for transaction costs.
- 4The new credit facility bears interest at LIBOR plus a margin of 0.65%.
- 5The agreement includes covenants requiring a maximum leverage ratio of 3.75x.
- 6A temporary increase in the leverage ratio to 4.75x is permitted following a 'Qualified Acquisition' (e.g., BTG plc acquisition), with step-downs thereafter.
- 7This refinancing activity indicates a focus on managing debt maturity and potentially securing favorable financing terms.